Effects of Statins on Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios in Patients With Coronary Artery Disease

Nozue, Tsuyoshi; Yamamoto, Shingo; Tohyama, Shugo; Fukui, Kazuki; Umezawa, Shigeo; Onishi, Yuko; Kunishima, Tomoyuki; Sato, Akira; Nozato, Toshihiro; Miyake, Shogo; Takeyama, Youichi; Morino, Yoshihiro; Takao, Yoshinori; Muramatsu, Toshiya; Hibi, Kiyoshi; Michishita, Ichiro

doi:10.1177/1074248412473202

Cited by 14 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipid-lowering therapies with strong statins have been shown to modify the concentrations of omega-3 and omega-6 PUFAs [50], [51]; however, we observed no significant difference in the proportion of individuals receiving statin therapy or in lipid profiles between PAD patients and control subjects (Table 1). In addition, neither GLA levels nor the EPA∶AA ratio were significantly correlated with lipid profiles in our study.…”

Section: Discussioncontrasting

confidence: 69%

Importance of Fatty Acid Compositions in Patients with Peripheral Arterial Disease

Gautam

Izawa²,

Shiba³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

ObjectiveImportance of fatty acid components and imbalances has emerged in coronary heart disease. In this study, we analyzed fatty acids and ankle-brachial index (ABI) in a Japanese cohort.MethodsPeripheral arterial disease (PAD) was diagnosed in 101 patients by ABI ≤0.90 and/or by angiography. Traditional cardiovascular risk factors and components of serum fatty acids were examined in all patients (mean age 73.2±0.9 years; 81 males), and compared with those in 373 age- and sex-matched control subjects with no evidence of PAD.ResultsThe presence of PAD (mean ABI: 0.71±0.02) was independently associated with low levels of gamma-linolenic acid (GLA) (OR: 0.90; 95% CI: 0.85–0.96; P = 0.002), eicosapentaenoic acid∶arachidonic acid (EPA∶AA) ratio (OR: 0.38; 95% CI: 0.17–0.86; P = 0.021), and estimated glomerular filtration rate (OR: 0.97; 95% CI: 0.96–0.98; P<0.0001), and with a high hemoglobin A1c level (OR: 1.34; 95% CI: 1.06–1.69; P = 0.013). Individuals with lower levels of GLA (≤7.95 µg/mL) and a lower EPA∶AA ratio (≤0.55) had the lowest ABI (0.96±0.02, N = 90), while the highest ABI (1.12±0.01, N = 78) was observed in individuals with higher values of both GLA and EPA∶AA ratio (P<0.0001).ConclusionA low level of GLA and a low EPA∶AA ratio are independently associated with the presence of PAD. Specific fatty acid abnormalities and imbalances could lead to new strategies for risk stratification and prevention in PAD patients.

show abstract

Section: Discussioncontrasting

confidence: 69%

Importance of Fatty Acid Compositions in Patients with Peripheral Arterial Disease

Gautam

Izawa²,

Shiba³

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Recently there has been a discussion on the relationship between statin treatment and n-3PUFA levels, although no causal relationship has been established [36,37]. The present study was cross-sectional, and no data on the changes of the lipid profile before and after statin treatment were available.…”

Section: Discussionmentioning

confidence: 93%

Association of atherosclerosis-related markers and its relationship to n-3 polyunsaturated fatty acids levels with a prevalence of coronary artery disease in an urban area in Japan

2013

View full text Add to dashboard Cite

Higher intakes of fish and n-3 polyunsaturated fatty acids (n-3PUFAs: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are associated with a reduced risk of coronary artery disease (CAD). We investigated the relationships between fish-derived n-3PUFAs and prevalence of CAD, and to assess the association of n-3PUFAs with atherosclerosis-related markers in an urban area. This study was designed as a hospital-based cross-sectional study on 649 consecutive outpatients who had undergone regular examinations between April 2009 and October 2009. After adjustments for the coronary risk factors in a multilogistic regression analysis of variables for which a significant difference was identified between the group of patients with a prevalence of CAD and the group with no prevalence of CAD, the multivariable odds ratio (95 % confidence interval) was 0.394 (0.205/0.760; P = 0.005) for the highest (92.4-373.5 μg/ml) versus lowest (6.2-40.0 μg/ml) quartile of serum EPA values and 0.433 (0.228/0.824; P = 0.011) for the highest (160.7-451.8 μg/ml) versus lowest (35.7-100.7 μg/ml) quartile of serum DHA values. Multivariate regression analyses after adjustment for risk factors showed that higher serum EPA and DHA levels were independent variables of a higher level of serum apolipoprotein A-1, a major compound of high-density lipoprotein. However, the results suggested that there might be conflicting effects of EPA and DHA in regard of the serum levels of other lipid markers. This cross-sectional study suggests that higher serum levels of n-3PUFAs were associated with a lower prevalence of CAD and an increase in serum apolipoprotein A-1 level, even in an urban area.

show abstract

“…The effects of statins on serum n-3 to n-6 PUFAs levels and these ratios have not been fully evaluated. Recently, we reported that pitavastatin decreased serum docosahexaenoic acid (DHA)/arachidonic acid (AA) ratio, whereas pravastatin had no effect on this ratio [ 6 ]. However, Nakamura et al reported that pravastatin and simvastatin decreased serum eicosapentaenoic acid (EPA)/AA ratio [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia

Nozue

Michishita

2015

Lipids Health Dis

Self Cite

View full text Add to dashboard Cite

BackgroundThe effects of statins on serum n-3 to n-6 polyunsaturated fatty acids (PUFAs) levels have not been fully evaluated. We examined the effects of two types of statins (rosuvastatin and pitavastatin) on serum PUFAs levels and their ratios in patients with dyslipidemia.FindingsA total of 46 patients who were not receiving lipid-lowering therapy were randomly assigned to receive either 2.5 mg/day of rosuvastatin or 2 mg/day of pitavastatin. Serum PUFAs levels were measured at baseline, at 4 weeks, and at 12 weeks. Rosuvastatin was used to treat 23 patients, and the remaining 23 patients were treated using pitavastatin. Serum docosahexaenoic acid (DHA) levels decreased significantly at 12 weeks in both groups (rosuvastatin: from 169.6 to 136.3 μg/mL, p = 0.006; pitavastatin: from 188.6 to 153.9 μg/mL, p = 0.03). However, serum levels of eicosapentaenoic acid (EPA) and arachidonic acid (AA) did not change. In addition, the EPA/AA ratio did not change, whereas the DHA/AA ratio decreased significantly at 12 weeks in both groups (rosuvastatin: from 0.99 to 0.80, p = 0.01; pitavastatin: from 1.14 to 0.91, p = 0.003). No adverse events were observed during the study period.ConclusionsIn this small, open-label, pilot study, rosuvastatin and pitavastatin decreased serum DHA levels and the DHA/AA ratio in patients with dyslipidemia.

show abstract

Effects of Statins on Serum n-3 to n-6 Polyunsaturated Fatty Acid Ratios in Patients With Coronary Artery Disease

Abstract: Pitavastatin decreased the serum DHA/AA ratio, whereas pravastatin had no effect on this ratio. Neither pitavastatin nor pravastatin had an effect on the serum EPA/AA ratio in patients with coronary artery disease.

Cited by 14 publications

References 27 publications

Importance of Fatty Acid Compositions in Patients with Peripheral Arterial Disease

Importance of Fatty Acid Compositions in Patients with Peripheral Arterial Disease

Association of atherosclerosis-related markers and its relationship to n-3 polyunsaturated fatty acids levels with a prevalence of coronary artery disease in an urban area in Japan

Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia

Contact Info

Product

Resources

About